FDA Greenlights Moderna's mNEXSPIKE for High-Risk Groups
Published on: May 31, 2025, 11:48 a.m. | Source: Devdiscourse
The FDA approved Moderna's mNEXSPIKE COVID-19 vaccine for those aged 65+ and those aged 12-64 with risk factors. The approval arrives amid regulatory changes and fluctuating vaccine demands. Moderna aims for availability by the 2025-2026 season, focusing on mRNA technology as demand for existing vaccines wanes.
